BPC-157 vs TB-500
BPC-157 and TB-500 often turn up in the same tissue-repair literature, and they are easily confused. They are nonetheless two entirely different compounds with different origins and modes of action.
| BPC-157 | TB-500 | |
|---|---|---|
| Origin | Fragment of a protein found in gastric juice | Synthetic fragment of thymosin beta-4 |
| Structure | Pentadecapeptide – 15 amino acids | Short peptide fragment, often referred to as Tβ4 fragment 17-23 |
| Mechanism studied | Angiogenesis, growth factor signalling and mucosal protection | Actin binding and cell migration |
| Typical research models | Tendon, gut and muscle tissue | Cell migration and tissue remodelling |
| Solubility | Lyophilised, reconstituted in bacteriostatic water | Lyophilised, reconstituted in bacteriostatic water |
What the difference means
The two are often used in comparative set-ups because they touch overlapping processes from different angles – BPC-157 through signalling and blood vessel formation, TB-500 through actin dynamics and cell movement. We do not rank them against each other: that would presuppose an efficacy claim we have no basis for.
Why they get confused
Both are described as “healing peptides” in popular accounts, and that is where the confusion starts. The term says nothing about mechanism, and the two compounds share no common origin: BPC-157 is derived from a sequence found in gastric juice, while TB-500 is a synthetic fragment of thymosin beta-4, a protein found widely in tissue.
Being studied in overlapping models does not mean they do the same thing. The literature describes them as complementary approaches to tissue response, not as variants of each other.
What the literature actually examines
For BPC-157, much of the research centres on angiogenesis and growth factor signalling – that is, the formation of new blood vessels and how cells are told to carry out repair. Much of the work has been done in gastrointestinal and tendon models.
For TB-500, the starting point is actin, one of the cell's structural proteins. Thymosin beta-4 binds actin and affects how cells change shape and move. The studies therefore more often concern cell migration and tissue remodelling.
One line of research is mostly about signalling, the other mostly about cellular mechanics.
In practice in the laboratory
Both are supplied lyophilised and reconstituted in bacteriostatic water. Handling is in practice the same, and BPC & TB Blend is available for set-ups where both are included in the same vial.
Every batch we sell has a batch number, stated purity and test date on the certificate of analysis.
Frequently asked questions
Are BPC-157 and TB-500 the same?
No. They have different origins, different structures and different described mechanisms. BPC-157 is a 15-amino-acid pentadecapeptide derived from gastric juice; TB-500 is a synthetic fragment of thymosin beta-4.
Can they be used together in research?
They appear in comparative set-ups in the literature, and BPC & TB Blend supplies both in the same vial. We give no recommendation on combination, dosing or use.
Which one is better?
We cannot answer that question. A ranking would presuppose an efficacy claim, and these compounds are sold for research use only.
All material is sold exclusively for research purposes and laboratory use. This page gives no dosing, instructions for use or health claims. Read more about safety and regulation.